MedPath

BAYER AG

BAYER AG logo
🇩🇪Germany
Ownership
Public
Established
1863-08-01
Employees
99.7K
Market Cap
$30.1B
Website
http://www.bayer.com
Clinical Trials
Related News

A Study of a New Chemotherapy Agent in Combination With Cisplatin to Treat Small Cell Lung Cancer

Phase 1
Completed
Conditions
Carcinoma, Small Cell
Interventions
Drug: Sagopilone (BAY86-5302, ZK 219477)
Drug: Cisplatin
First Posted Date
2006-08-02
Last Posted Date
2014-11-04
Lead Sponsor
Bayer
Target Recruit Count
26
Registration Number
NCT00359359

Safety/Efficacy Study of Drospirenone/Estradiol to Treat Postmenopausal Chinese Women With Vasomotor Symptoms.

Phase 3
Completed
Conditions
Vasomotor Symptoms
Interventions
Drug: Estradiol/DRSP (Angeliq, BAY86-4891)
Drug: Placebo
First Posted Date
2006-07-26
Last Posted Date
2014-10-01
Lead Sponsor
Bayer
Target Recruit Count
249
Registration Number
NCT00356447

Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib

First Posted Date
2006-07-17
Last Posted Date
2014-12-30
Lead Sponsor
Bayer
Target Recruit Count
2
Registration Number
NCT00352859

ZK-Epo Given With Prednisone in Patients With Metastatic Androgen-independent Prostate Cancer

Phase 2
Completed
Conditions
Prostate Cancer
Interventions
Drug: Sagopilone (ZK 219477) + prednisone
First Posted Date
2006-07-10
Last Posted Date
2021-04-08
Lead Sponsor
Bayer
Target Recruit Count
53
Registration Number
NCT00350051

BAY88-8223, Dose Finding Study in Patients With HRPC

Phase 2
Completed
Conditions
Prostate Cancer
Neoplasm Metastasis
Interventions
Drug: Radium-223 dichloride (BAY88-8223)
First Posted Date
2006-06-15
Last Posted Date
2023-11-02
Lead Sponsor
Bayer
Target Recruit Count
122
Registration Number
NCT00337155

Fat Distribution in Healthy Early Postmenopausal Women

Phase 4
Completed
Conditions
Healthy
Postmenopause
Interventions
Drug: Placebo
Drug: Climodien / Lafamme (BAY86-5027)
First Posted Date
2006-06-09
Last Posted Date
2014-12-30
Lead Sponsor
Bayer
Target Recruit Count
67
Registration Number
NCT00335218

Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE, a Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement

Phase 3
Completed
Conditions
Prevention
Venous Thromboembolism
Interventions
Drug: Rivaroxaban (BAY59-7939)
Drug: Enoxaparin
First Posted Date
2006-05-31
Last Posted Date
2015-01-27
Lead Sponsor
Bayer
Target Recruit Count
2457
Registration Number
NCT00332020

Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin

Phase 3
Completed
Conditions
Venous Thromboembolism
Interventions
Drug: Rivaroxaban (BAY59-7939)
Drug: Enoxaparin
First Posted Date
2006-05-25
Last Posted Date
2014-10-28
Lead Sponsor
Bayer
Target Recruit Count
4541
Registration Number
NCT00329628

Effect of Aprotinin on Transfusion Requirements in Patients Undergoing Elective Spinal Fusion Surgery

Phase 3
Terminated
Conditions
Postoperative Hemorrhage
Blood Loss, Surgical
Interventions
Drug: Placebo
Drug: Trasylol (Aprotinin, BAYA0128)
First Posted Date
2006-05-18
Last Posted Date
2019-06-04
Lead Sponsor
Bayer
Target Recruit Count
54
Registration Number
NCT00327379

ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer

Phase 2
Completed
Conditions
Ovarian Neoplasms
Interventions
Drug: Sagopilone (ZK 219477) + carboplatin
First Posted Date
2006-05-12
Last Posted Date
2021-04-08
Lead Sponsor
Bayer
Target Recruit Count
45
Registration Number
NCT00325351
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy